Futura Medical has advanced transdermal technology which can be incorporated into formulations of well characterised drugs to improve performance and extend their uses. 2015 was expected to be a busy year for the company and interim results show that management is delivering on expectations Despite that, market reaction to the headline data from the pain portfolio trial was disappointing, as this reduced risk and provided a catalyst to value appreciation. Further data analysis has demonstrated that neither topical nor oral formulations of commercial comparator products outperformed the equivalent FUM NSAID.
09 Sep 2015
Interims – Delivering on a number of targets
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Interims – Delivering on a number of targets
Futura Medical plc (FUM:LON) | 40.1 0.7 4.4% | Mkt Cap: 120.9m
- Published:
09 Sep 2015 -
Author:
Mark Brewer -
Pages:
8
Futura Medical has advanced transdermal technology which can be incorporated into formulations of well characterised drugs to improve performance and extend their uses. 2015 was expected to be a busy year for the company and interim results show that management is delivering on expectations Despite that, market reaction to the headline data from the pain portfolio trial was disappointing, as this reduced risk and provided a catalyst to value appreciation. Further data analysis has demonstrated that neither topical nor oral formulations of commercial comparator products outperformed the equivalent FUM NSAID.